FXYD4: A Drug Target / Disease Biomarker (G53828)

Target Name: FXYD4

NCBI ID: G53828

FXYD4

FXYD4: A Drug Target / Disease Biomarker

FXYD4, also known as Fasorinib, is a drug target (or biomarker) that is being targeted for development as a treatment for various diseases, including cancer. It is a small protein that is expressed in many different tissues throughout the body, including the brain, heart, and lungs.

FXYD4 has been shown to play a role in a number of different diseases, including cancer. For example, studies have shown that high levels of FXYD4 have been associated with an increased risk of certain types of cancer, such as lung and breast cancer. Additionally, FXYD4 has also been shown to contribute to the development of certain types of cancer, such as neuroendocrine tumors.

FXYD4 is also of interest as a potential biomarker for cancer. By measuring the levels of FXYD4 in tissues and fluids, researchers can potentially monitor the effectiveness of treatments for cancer. This is because FXYD4 is known to be expressed in many different types of cancer, and researchers may be able to use it as a marker to track the progress of a treatment.

FXYD4 is also of interest as a potential drug target for other diseases. For example, studies have shown that FXYD4 is involved in a number of different signaling pathways, including the TGF-β pathway. This means that FXYD4 may be a good candidate for drugs that are designed to target this pathway. Additionally, FXYD4 has also been shown to play a role in the regulation of cell growth and differentiation, which may make it a good candidate for drugs that are aimed at preventing or reversing these processes.

Despite the potential benefits of FXYD4 as a drug target or biomarker, there are also some potential risks and challenges that need to be considered. For example, studies have shown that FXYD4 can cause some side effects when expressed in cells, such as increased blood pressure and anemia. Additionally, there may be concerns about the potential impact of FXYD4 on other proteins that are important for normal cell function.

Overall, FXYD4 is a protein that is being targeted for development as a drug target or biomarker for a number of different diseases. While there are still some potential risks and challenges that need to be considered, studies have shown that it has the potential to be a valuable tool for the treatment of a wide range of conditions.

Protein Name: FXYD Domain Containing Ion Transport Regulator 4

The "FXYD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FXYD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets